Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Short Interest Update

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was the target of a significant decline in short interest during the month of November. As of November 30th, there was short interest totalling 3,390,000 shares, a decline of 9.4% from the November 15th total of 3,740,000 shares. Based on an average daily volume of 761,800 shares, the short-interest ratio is currently 4.4 days.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Bank of America lifted their price objective on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Scotiabank boosted their price target on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the company a “sector outperform” rating in a research report on Friday, November 1st. StockNews.com downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, November 28th. Canaccord Genuity Group lifted their price objective on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a “buy” rating in a research note on Friday, November 1st. Finally, Raymond James increased their target price on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an “outperform” rating in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $298.09.

Alnylam Pharmaceuticals Trading Down 0.6 %

NASDAQ ALNY opened at $243.99 on Tuesday. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. The stock’s 50-day simple moving average is $266.55 and its two-hundred day simple moving average is $250.23. Alnylam Pharmaceuticals has a twelve month low of $141.98 and a twelve month high of $304.39. The company has a market capitalization of $31.47 billion, a price-to-earnings ratio of -93.13 and a beta of 0.32.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The company had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. The company’s quarterly revenue was down 33.3% compared to the same quarter last year. During the same quarter last year, the company posted $1.15 earnings per share. Research analysts forecast that Alnylam Pharmaceuticals will post -2.21 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Tolga Tanguler sold 1,469 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $368,689.62. Following the completion of the sale, the executive vice president now owns 13,191 shares in the company, valued at $3,310,677.18. This trade represents a 10.02 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Yvonne Greenstreet sold 5,219 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $1,309,864.62. Following the completion of the transaction, the chief executive officer now owns 78,880 shares in the company, valued at approximately $19,797,302.40. The trade was a 6.21 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 10,122 shares of company stock valued at $2,540,455. Insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Cetera Advisors LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 1st quarter valued at about $238,000. Wealth Enhancement Advisory Services LLC lifted its position in Alnylam Pharmaceuticals by 40.2% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 4,131 shares of the biopharmaceutical company’s stock valued at $1,004,000 after purchasing an additional 1,184 shares during the last quarter. Raymond James & Associates boosted its stake in shares of Alnylam Pharmaceuticals by 7.2% during the second quarter. Raymond James & Associates now owns 16,257 shares of the biopharmaceutical company’s stock valued at $3,950,000 after purchasing an additional 1,089 shares during the period. Chapin Davis Inc. bought a new position in shares of Alnylam Pharmaceuticals in the second quarter worth approximately $200,000. Finally, Pallas Capital Advisors LLC purchased a new position in shares of Alnylam Pharmaceuticals in the second quarter worth $486,000. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.